Skip to main content
U.S. flag

An official website of the United States government

Inhibition of Drp1 ameliorates synaptic depression, Aβ deposition, and cognitive impairment in an Alzheimer’s disease model

Bibliographic

Year of Publication:
2017
Contact PI Name:
Dong-Gyu Jo
Contact PI Affiliation:
School of Pharmacy, Sungkyunkwan University, Korea
Co-Authors:
S.H. Baek, S.J. Park, J.I. Jeong, S.H. Kim, J. Han, J.W. Kyung, S.H. Baik, Y. Choi, B.Y. Choi, J.S. Park, G. Bahn, J.H. Shin, D.S. Jo, J.Y. Lee, C.G. Jang, T.V. Arumugam, J. Kim, J.W. Han, J.Y. Koh, D.H. Cho
Primary Reference (PubMED ID):
Funding Source:
Korean Health 21 R&D Project
Korea–UK Collaborative Alzheimer’s Disease Research Project
Korean Ministry of Education, Science and Technology (MEST)
National Research Foundation of Korea (NRF)
Korean Ministry of Health and Welfare and Family Affairs
Study Goal and Principal Findings:

Excessive mitochondrial fission is a prominent early event and contributes to mitochondrial dysfunction, synaptic failure, and neuronal cell death in the progression of Alzheimer's disease (AD). However, it remains to be determined whether inhibition of excessive mitochondrial fission is beneficial in mammal models of AD. To determine whether dynamin-related protein 1 (Drp1), a key regulator of mitochondrial fragmentation, can be a disease-modifying therapeutic target for AD, we examined the effects of Drp1 inhibitor on mitochondrial and synaptic dysfunctions induced by oligomeric amyloid-β (Aβ) in neurons and neuropathology and cognitive functions in Aβ precursor protein/presenilin 1 double-transgenic AD mice. Inhibition of Drp1 alleviates mitochondrial fragmentation, loss of mitochondrial membrane potential, reactive oxygen species production, ATP reduction, and synaptic depression in Aβ-treated neurons. Furthermore, Drp1 inhibition significantly improves learning and memory and prevents mitochondrial fragmentation, lipid peroxidation, BACE1 expression, and Aβ deposition in the brain in the AD model. These results provide evidence that Drp1 plays an important role in Aβ-mediated and AD-related neuropathology and in cognitive decline in an AD animal model. Therefore, inhibiting excessive Drp1-mediated mitochondrial fission may be an efficient therapeutic avenue for AD.

SIGNIFICANCE STATEMENT Mitochondrial fission relies on the evolutionary conserved dynamin-related protein 1 (Drp1). Drp1 activity and mitochondria fragmentation are significantly elevated in the brains of sporadic Alzheimer's disease (AD) cases. In the present study, we first demonstrated that the inhibition of Drp1 restored amyloid-β (Aβ)-mediated mitochondrial dysfunctions and synaptic depression in neurons and significantly reduced lipid peroxidation, BACE1 expression, and Aβ deposition in the brain of AD mice. As a result, memory deficits in AD mice were rescued by Drp1 inhibition. These results suggest that neuropathology and combined cognitive decline can be attributed to hyperactivation of Drp1 in the pathogenesis of AD. Therefore, inhibitors of excessive mitochondrial fission, such as Drp1 inhibitors, may be a new strategy for AD.

Bibliographic Notes:
The paper lists both Dong-Hyung Cho (Graduate School of East-West Medical Science, Kyung Hee University, Korea) and Dong-Gyu Jo (School of Pharmacy, Sungkyunkwan University, Korea) as corresponding authors on this paper.

Therapeutic Agent

Therapeutic Information:
Therapy Type:
Small Molecule
Therapeutic Agent:
Mitochondrial Division Inhibitor (mdivi-1)
Therapeutic Target:
Dynamin-Related Protein 1 (Drp1)
Therapeutic Notes:
Dynamin-Related Protein 1 (Drp1) has been nominated as a potential target for AD. Nominated targets are obtained from several sources, including the National Institute on Aging's Accelerating Medicines Partnership in Alzheimer's Disease (AMP-AD) consortium. Targets have been identified using computational analyses of high-dimensional genomic, proteomic and/or metabolomic data derived from human samples. See Agora link for more information.

Animal Model

Model Information:
Species:
Mouse
Model Type:
APPxPS1
Strain/Genetic Background:
C57BL/6J

Experimental Design

Is the following information reported in the study?:
Power/Sample Size Calculation
Randomized into Groups
Blinded for Treatment
Blinded for Outcome Measures
Pharmacokinetic Measures
Pharmacodynamic Measures
Toxicology Measures
ADME Measures
Biomarkers
Dose
Formulation
Route of Delivery
Duration of Treatment
Frequency of Administration
Age of Animal at the Beginning of Treatment
Age of Animal at the End of Treatment
Sex as a Biological Variable
Study Balanced for Sex as a Biological Variable
Number of Premature Deaths
Number of Excluded Animals
Statistical Plan
Genetic Background
Inclusion/Exclusion Criteria Included
Conflict of Interest
Experiment Notes

Note: The authors state that sample sizes for all experiments were determined by power analyses based on previously published data – however, none of these previously published data are cited nor is there is a reference provided.

Outcomes

Outcome Measured
Outcome Parameters
Behavioral
Morris Water Maze
Passive Avoidance Test
Motor Function
Swimming Speed
Histopathology
beta Amyloid Deposits
beta Amyloid Load
Activated Astrocytes
Activated Microglia
Biochemical
Amyloid Precursor Protein (APP)
APP-CTF99 (CTF beta)
Adenosine Triphosphate (ATP)
beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1)
beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) mRNA
Mitochondrial Membrane Potential
Reactive Oxygen Species (ROS)
Immunochemistry
4-hydroxy-2-nonenal (HNE)
Brain-beta Amyloid Deposits
Glial Fibrillary Acidic Protein (GFAP)
Ionized Calcium Binding Adaptor Molecule 1 (Iba1)
Microtubule-Associated Protein 2 (MAP2)
Cell Biology
Mitochondrial Length
Synaptic Vesicle Exocytosis
Toxicology
Body Weight
Organ Weight